Eledon Pharmaceuticals Inc - Asset Resilience Ratio
Eledon Pharmaceuticals Inc (ELDN) has an Asset Resilience Ratio of 46.52% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital position of Eledon Pharmaceuticals Inc to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2025)
This chart shows how Eledon Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Eledon Pharmaceuticals Inc (ELDN) total assets.
Liquid Assets Composition Over Time
This chart breaks down Eledon Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read Eledon Pharmaceuticals Inc balance sheet liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $110.53 Million | 46.52% |
| Total Liquid Assets | $110.53 Million | 46.52% |
Asset Resilience Insights
- Very High Liquidity: Eledon Pharmaceuticals Inc maintains exceptional liquid asset reserves at 46.52% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Eledon Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Eledon Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND |
Biotechnology | 16.06% |
|
Genscript Biotech Corporation
F:G51 |
Biotechnology | 13.79% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
89bio Inc
NASDAQ:ETNB |
Biotechnology | 71.60% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 2.66% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
Annual Asset Resilience Ratio for Eledon Pharmaceuticals Inc (2015–2025)
The table below shows the annual Asset Resilience Ratio data for Eledon Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 46.52% | $110.53 Million | $237.60 Million | -20.91pp |
| 2024-12-31 | 67.43% | $119.63 Million | $177.41 Million | +30.50pp |
| 2023-12-31 | 36.93% | $46.49 Million | $125.89 Million | -- |
| 2022-12-31 | 0.00% | $0.00 | $92.79 Million | -- |
| 2016-12-31 | 14.03% | $4.17 Million | $29.76 Million | -44.72pp |
| 2015-12-31 | 58.75% | $39.93 Million | $67.97 Million | -- |
About Eledon Pharmaceuticals Inc
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for C… Read more